JP7622229B2 - N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド - Google Patents
N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド Download PDFInfo
- Publication number
- JP7622229B2 JP7622229B2 JP2023536454A JP2023536454A JP7622229B2 JP 7622229 B2 JP7622229 B2 JP 7622229B2 JP 2023536454 A JP2023536454 A JP 2023536454A JP 2023536454 A JP2023536454 A JP 2023536454A JP 7622229 B2 JP7622229 B2 JP 7622229B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cyanothiazolidin
- oxoethyl
- carboxamide
- quinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025005438A JP7744538B2 (ja) | 2020-12-17 | 2025-01-15 | N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063126593P | 2020-12-17 | 2020-12-17 | |
| US63/126,593 | 2020-12-17 | ||
| PCT/IB2021/061839 WO2022130270A1 (en) | 2020-12-17 | 2021-12-16 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025005438A Division JP7744538B2 (ja) | 2020-12-17 | 2025-01-15 | N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023554405A JP2023554405A (ja) | 2023-12-27 |
| JP2023554405A5 JP2023554405A5 (cg-RX-API-DMAC7.html) | 2024-11-06 |
| JP7622229B2 true JP7622229B2 (ja) | 2025-01-27 |
Family
ID=79164845
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023536454A Active JP7622229B2 (ja) | 2020-12-17 | 2021-12-16 | N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド |
| JP2025005438A Active JP7744538B2 (ja) | 2020-12-17 | 2025-01-15 | N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025005438A Active JP7744538B2 (ja) | 2020-12-17 | 2025-01-15 | N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド |
Country Status (20)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY39569A (es) * | 2020-12-17 | 2022-07-29 | Astrazeneca Ab | N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas |
| AU2023288645A1 (en) * | 2022-06-21 | 2025-02-13 | Astrazeneca Ab | Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- 6-morpholinoquinoline-4-carboxamide |
| CN119562951A (zh) * | 2022-06-21 | 2025-03-04 | 阿斯利康(瑞典)有限公司 | N-(2-(4-氰基噻唑烷-3-基)-2-氧代乙基)-喹啉-4-甲酰胺 |
| WO2026119802A1 (en) | 2024-12-02 | 2026-06-11 | Astrazeneca Ab | Dosing regimen for the treatment of fap-mediated conditions |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003515585A (ja) | 1999-11-30 | 2003-05-07 | フェリング ベスローテン フェンノートシャップ | 新規抗糖尿病薬 |
| JP2009507011A (ja) | 2005-09-02 | 2009-02-19 | フェリング ベスローテン フェンノートシャップ | Fap阻害剤 |
| WO2013107820A1 (en) | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW521072B (en) | 1997-06-02 | 2003-02-21 | Meiji Seika Kaisha | 4-quinolinol derivatives and fungicides containing the same as an active ingredient used for agriculture and horticulture |
| FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
| DE10006453A1 (de) | 2000-02-14 | 2001-08-16 | Bayer Ag | Piperidylcarbonsäuren als Integrinantagonisten |
| GB0010183D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| GB0010188D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| AU2001277754B2 (en) | 2000-08-10 | 2005-09-29 | Mitsubishi Tanabe Pharma Corporation | Proline derivatives and use thereof as drugs |
| JP2003026698A (ja) | 2000-09-27 | 2003-01-29 | Tokyo Inst Of Technol | 新規化合物、固定化物及び蛋白質のスクリーニング方法 |
| GB0125445D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Protease Inhibitors |
| AU2004207731B2 (en) | 2003-01-31 | 2009-08-13 | Sanwa Kagaku Kenkyusho Co., Ltd. | Compound inhibiting dipeptidyl peptidase iv |
| EP2210607B1 (en) * | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| WO2005087742A1 (en) | 2004-03-08 | 2005-09-22 | Exelixis, Inc. | Metabolic kinase modulators and methods of use as pesticides |
| TWI366438B (en) | 2004-08-12 | 2012-06-21 | Ishihara Sangyo Kaisha | Fungicidal composition containing acid amide derivative |
| WO2007017423A2 (en) | 2005-08-11 | 2007-02-15 | F. Hoffmann-La Roche Ag | Pharmaceutical composition comprising a dpp-iv inhibitor |
| JP2010510246A (ja) | 2006-11-21 | 2010-04-02 | スミスクライン ビーチャム コーポレーション | アミド抗ウイルス化合物 |
| CN102884059B (zh) | 2010-03-11 | 2015-08-26 | 大日本住友制药株式会社 | N-酰基环胺衍生物或其可药用盐 |
| EP4706663A3 (en) | 2011-08-30 | 2026-05-20 | Trustees Of Tufts College | FAP-ACTIVATED PROTEASOME INHIBITORS USED TO TREAT SOLID TUMORS |
| UA110862C2 (uk) | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
| EP2874632B1 (en) | 2012-07-23 | 2020-06-17 | Sphaera Pharma Pte. Ltd | Triazine compound having pi3k-alpha and mtor inhibiting activity |
| MX2016012573A (es) | 2014-03-28 | 2018-02-19 | Sunshine Lake Pharma Co Ltd | Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos. |
| JP2017513954A (ja) | 2014-04-22 | 2017-06-01 | ニンバス アイリス, インコーポレイテッド | Irak阻害剤およびその使用 |
| AU2015315174B2 (en) | 2014-09-10 | 2019-12-12 | Epizyme, Inc. | Smyd inhibitors |
| WO2016061751A1 (en) * | 2014-10-22 | 2016-04-28 | Merck Sharp & Dohme Corp. | Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors |
| WO2017189569A1 (en) | 2016-04-25 | 2017-11-02 | Trustees Of Tufts College | Multimediator dpp4 and fap inhibitors, and uses related thereto |
| CN118359610A (zh) | 2016-09-16 | 2024-07-19 | 生命医药有限责任公司 | Menin-mll相互作用的抑制剂 |
| WO2018161033A1 (en) | 2017-03-02 | 2018-09-07 | Wright, Adrian | Small molecule ire1-alpha inhibitors |
| CN108690043B (zh) | 2017-04-11 | 2019-10-18 | 东莞东阳光科研发有限公司 | 喹啉类衍生物及其制备方法和用途 |
| US11358940B2 (en) | 2017-04-20 | 2022-06-14 | The Regents Of The University Of California | K-Ras modulators |
| US11584744B2 (en) | 2017-06-23 | 2023-02-21 | University Of Washington | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them |
| JP7365332B2 (ja) | 2017-08-07 | 2023-10-19 | ジョイント・ストック・カンパニー “バイオキャド” | Cdk8/19阻害薬としての新規ヘテロ環式化合物 |
| EP3700527A4 (en) | 2017-10-25 | 2021-03-10 | Children's Medical Center Corporation | PAPD5 INHIBITORS AND METHOD OF USING THEM |
| AU2018386298B2 (en) | 2017-12-15 | 2023-09-07 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| JP2021506862A (ja) | 2017-12-19 | 2021-02-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Tlr7/8アンタゴニストおよびそれらの使用 |
| PH12020551205A1 (en) | 2018-02-06 | 2021-04-19 | Univ Heidelberg | Fap inhibitors |
| SG11202100818RA (en) | 2018-07-31 | 2021-02-25 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| US12662494B2 (en) | 2018-08-08 | 2026-06-23 | Sumitomo Pharma Co., Ltd. | Optically active bridged piperidine derivative |
| TWI815954B (zh) | 2018-08-27 | 2023-09-21 | 日商住友製藥股份有限公司 | 光學活性氮雜雙環衍生物 |
| US10815241B2 (en) | 2018-08-27 | 2020-10-27 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active azabicyclo ring derivative |
| CN113811529A (zh) * | 2018-12-21 | 2021-12-17 | 普拉西斯生物技术有限责任公司 | 成纤维细胞激活蛋白抑制剂 |
| US12559487B2 (en) | 2019-09-27 | 2026-02-24 | Sumitomo Pharma Co., Ltd. | Crosslinked optically active secondary amine derivative |
| BR112022008041A2 (pt) | 2019-11-06 | 2022-08-16 | Yuhan Corp | Compostos de pirrolidina e piperidina |
| UY39569A (es) * | 2020-12-17 | 2022-07-29 | Astrazeneca Ab | N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas |
-
2021
- 2021-12-16 UY UY0001039569A patent/UY39569A/es unknown
- 2021-12-16 WO PCT/IB2021/061839 patent/WO2022130270A1/en not_active Ceased
- 2021-12-16 IL IL303655A patent/IL303655A/en unknown
- 2021-12-16 CR CR20230314A patent/CR20230314A/es unknown
- 2021-12-16 AU AU2021403827A patent/AU2021403827B2/en active Active
- 2021-12-16 US US18/257,123 patent/US20240101549A1/en active Pending
- 2021-12-16 PE PE2023001909A patent/PE20232046A1/es unknown
- 2021-12-16 JP JP2023536454A patent/JP7622229B2/ja active Active
- 2021-12-16 KR KR1020237023914A patent/KR20230122080A/ko active Pending
- 2021-12-16 CN CN202180084189.5A patent/CN116745291B/zh active Active
- 2021-12-16 CA CA3204318A patent/CA3204318A1/en active Pending
- 2021-12-16 AR ARP210103519A patent/AR124379A1/es unknown
- 2021-12-16 EP EP21834914.0A patent/EP4263535A1/en active Pending
- 2021-12-16 MX MX2023007287A patent/MX2023007287A/es unknown
- 2021-12-16 TW TW110147244A patent/TW202239407A/zh unknown
-
2023
- 2023-06-12 US US18/332,897 patent/US11858924B2/en active Active
- 2023-06-14 DO DO2023000124A patent/DOP2023000124A/es unknown
- 2023-06-15 CL CL2023001763A patent/CL2023001763A1/es unknown
- 2023-06-15 SA SA523441175A patent/SA523441175B1/ar unknown
- 2023-07-05 CO CONC2023/0008921A patent/CO2023008921A2/es unknown
- 2023-07-14 EC ECSENADI202353033A patent/ECSP23053033A/es unknown
-
2024
- 2024-09-18 AU AU2024219819A patent/AU2024219819B2/en active Active
-
2025
- 2025-01-15 JP JP2025005438A patent/JP7744538B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003515585A (ja) | 1999-11-30 | 2003-05-07 | フェリング ベスローテン フェンノートシャップ | 新規抗糖尿病薬 |
| JP2009507011A (ja) | 2005-09-02 | 2009-02-19 | フェリング ベスローテン フェンノートシャップ | Fap阻害剤 |
| WO2013107820A1 (en) | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2023000124A (es) | 2023-07-09 |
| US20240101549A1 (en) | 2024-03-28 |
| MX2023007287A (es) | 2023-07-03 |
| WO2022130270A1 (en) | 2022-06-23 |
| EP4263535A1 (en) | 2023-10-25 |
| AU2021403827A1 (en) | 2023-07-27 |
| JP7744538B2 (ja) | 2025-09-25 |
| CO2023008921A2 (es) | 2023-07-21 |
| AU2021403827B2 (en) | 2024-07-25 |
| JP2025081297A (ja) | 2025-05-27 |
| ECSP23053033A (es) | 2023-08-31 |
| TW202239407A (zh) | 2022-10-16 |
| UY39569A (es) | 2022-07-29 |
| US11858924B2 (en) | 2024-01-02 |
| CL2023001763A1 (es) | 2023-11-17 |
| CN116745291B (zh) | 2026-06-30 |
| IL303655A (en) | 2023-08-01 |
| PE20232046A1 (es) | 2023-12-27 |
| CR20230314A (es) | 2023-08-18 |
| CA3204318A1 (en) | 2022-06-23 |
| US20230312550A1 (en) | 2023-10-05 |
| KR20230122080A (ko) | 2023-08-22 |
| AU2021403827A9 (en) | 2024-10-17 |
| SA523441175B1 (ar) | 2024-08-29 |
| AU2024219819B2 (en) | 2026-06-04 |
| JP2023554405A (ja) | 2023-12-27 |
| AU2024219819A1 (en) | 2024-10-10 |
| CN116745291A (zh) | 2023-09-12 |
| AR124379A1 (es) | 2023-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7744538B2 (ja) | N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド | |
| US12624033B2 (en) | KRAS inhibitors | |
| AU2018351400B2 (en) | Dihydropyrimidine compounds and uses thereof in medicine | |
| US11236087B2 (en) | Highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis B virus (HBV) | |
| CN119301132A (zh) | 用于治疗癌症的卤代吲哚大环化合物 | |
| RU2332412C2 (ru) | Производные пиразола | |
| BRPI0714359A2 (pt) | inibidores de pirrolotriazina cinase | |
| TW200831518A (en) | Imidazothiazole derivatives | |
| BR102015024618A2 (pt) | compostos inibidores de quinase de ligação de tank | |
| US11447479B2 (en) | Compounds active towards nuclear receptors | |
| TWI919070B (zh) | 醯胺雜芳香族化合物及其用途 | |
| JP2020537671A (ja) | ピリミジンTBK/IKKεインヒビター化合物およびそれらの使用 | |
| WO2015125785A1 (ja) | 複数置換基を有するピラゾロン誘導体 | |
| JP2025525344A (ja) | N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド | |
| US20240317748A1 (en) | Carbonyl substituted diazaspiro compounds and its use | |
| JP2023508955A (ja) | 脂質異常症の治療に適した新規な化合物 | |
| JP2009298713A (ja) | イミダゾチアゾール誘導体 | |
| EA048482B1 (ru) | N-(2-(4-цианотиазолидин-3-ил)-2-оксоэтил)хинолин-4-карбоксамиды | |
| EA051853B1 (ru) | N-(2-(4-цианотиазолидин-3-ил)-2-оксоэтил)хинолин-4-карбоксамиды | |
| US20250122183A1 (en) | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | |
| EA052200B1 (ru) | Амидогетероароматические соединения, применимые в лечении заболеваний печени | |
| WO2025202922A1 (en) | Imidazopyridazine il-17 inhibitor compounds | |
| CN121127467A (zh) | 作为ripk1抑制剂的异噁唑烷及其用途 | |
| JP2026511536A (ja) | メニンのアゴニズムを介してがんに対して作用する1-h-ピロロ[2,3-c]ピリジン化合物 | |
| EA050746B1 (ru) | Карбонилзамещенные диазаспиросоединения и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241024 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241024 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20241024 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241217 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250115 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7622229 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |